Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Clicks: 382
ID: 267837
2013
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #24 of 86 articles by views in Vaccine

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
In adults aged 70 years and older previously vaccinated with PPSV23, PCV13 was significantly more immunogenic than PPSV23 for most of the common serotypes and for serotype 6A. The OPA responses after a follow-on dose of PCV13 one year later indicate that a prior dose of PPSV23, but not PCV13, dimini …
Reference Key
la2013vaccineimmunogenicity Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jackson LA;Gurtman A;Rice K;Pauksens K;Greenberg RN;Jones TR;Scott DA;Emini EA;Gruber WC;Schmoele-Thoma B;;
Journal Vaccine
Year 2013
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/23688527
Keywords
immunization National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't female male aged 80 and over Clinical Trial Phase III Randomized Controlled Trial Antibodies Double-Blind Method Multicenter Study United States pneumonia vaccines streptococcus pneumoniae / immunology* conjugate / immunology conjugate / therapeutic use pneumococcal / immunology bacterial / blood bacterial / immunology pneumococcal vaccines* / adverse effects polysaccharides conjugate / adverse effects pneumococcal / prevention & control* pmid:23688527 doi:10.1016/j.vaccine.2013.05.010 lisa a jackson alejandra gurtman beate schmoele-thoma secondary* pneumococcal vaccines* / immunology pneumococcal vaccines* / therapeutic use

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.